-
06:58:24 PM

MRK Stock News

03/16/23 4:05 PM
NYSE : MRK
clinical trial
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Merck, known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. Merck is notifying study investigators that patients in this arm of the study should be switched to a standard of care, unless their physician considers the patient is benefitting from MK-7684A alone.
RHEA-AI
neutral
03/10/23 6:45 AM
NYSE : MRK
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
Merck, known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group today announced that the Phase 2/ 3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’ s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival for the first-line treatment of...
RHEA-AI
neutral
03/06/23 12:01 PM
NYSE : MRK
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
Merck, known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, Merck’ s novel investigational activin signaling inhibitor biologic, in combination with stable background therapy for the treatment of adult patients with pulmonary arterial hypertension.
RHEA-AI
neutral
03/06/23 12:00 PM
NYSE : MRK
clinical trial
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
Merck, known as MSD outside of the United States and Canada, today announced results from the Phase 2 b clinical trial evaluating MK-0616, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 inhibitor in adults with hypercholesterolemia. At week 8, all doses of MK-0616 significantly reduced LDL-C compared to placebo and the...
RHEA-AI
neutral
03/06/23 6:45 AM
NYSE : MRK
fda approval
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
Merck, known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration has approved the addition of the intramuscular route of administration to the United States Product Insert for Merck’ s MMRV family of vaccines: M-M-R ® II, VARIVAX ®, and ProQuad ®. While these vaccines have a long history in the U.S., until now...
RHEA-AI
positive
03/02/23 9:00 AM
NYSE : MRK
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
AstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration will convene a meeting of the Oncologic Drugs Advisory Committee to discuss the supplemental new drug application for use of LYNPARZA in combination with abiraterone and prednisone or prednisolone for the treatment of...
RHEA-AI
neutral
03/01/23 6:45 AM
NYSE : MRK
clinical trial
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
Merck, known as MSD outside of the United States and Canada, announced today that the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’ s anti-PD-1 therapy, met one of its dual primary endpoints, event-free survival, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer. The U.S. Food and Drug...
RHEA-AI
neutral